Tekla Capital Management LLC Theravance Biopharma, Inc. Transaction History

Tekla Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$8.33 - $12.96 $5.47 Million - $8.51 Million	-656,296 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$14.52 - $22.46 $2.9 Million - $4.49 Million	200,000 Added 43.83%	656,296 $9.53 Million
Q4 2020 Feb 12, 2021	BUY	$14.89 - $20.16 $2.35 Million - $3.18 Million	157,826 Added 52.88%	456,296 $8.11 Million
Q3 2020 Nov 13, 2020	BUY	$14.79 - $22.49 $1.03 Million - $1.57 Million	69,634 Added 30.43%	298,470 $4.41 Million
Q1 2020 May 14, 2020	BUY	$17.84 - $31.21 $1.98 Million - $3.47 Million	111,111 Added 94.38%	228,836 $5.29 Million
Q4 2019 Feb 13, 2020	BUY	$16.12 - $25.89 $1.15 Million - $1.85 Million	71,624 Added 155.36%	117,725 $3.05 Million
Q3 2019 Nov 13, 2019	BUY	$16.51 - $23.78 $761,127 - $1.1 Million	46,101 New	46,101 $898,000
Q4 2018 Feb 13, 2019	SELL	$22.52 - $35.07 $182,029 - $283,470	-8,083 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$23.37 - $29.71 $188,899 - $240,145	8,083 New	8,083 $196,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $636M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.